Related Experiment Videos
Vaccine therapy for prostate cancer
B A Tjoa1, A A Elgamal, G P Murphy
1Cancer Research Division, Pacific Northwest Cancer Foundation, Northwest Hospital, Seattle, Washington, USA.
The Urologic Clinics of North America
|June 11, 1999
Summary
Dendritic cell vaccine therapy shows promise for advanced prostate cancer. This treatment, using prostate-specific membrane antigen (PSMA) pulsed cells, generated immune responses with minimal side effects in hormone-refractory patients.
Area of Science:
- Oncology
- Immunology
- Vaccine Therapy
Background:
- Hormone therapy resistance is a challenge in advanced prostate cancer.
- Novel therapeutic strategies are needed for patients with refractory disease.
Purpose of the Study:
- To evaluate the efficacy and safety of dendritic cell vaccine therapy in patients with hormone-refractory prostate cancer.
- To assess immune responses induced by prostate-specific membrane antigen (PSMA) pulsed dendritic cells.
Main Methods:
- Administration of autologous dendritic cells pulsed with prostate-specific membrane antigen (PSMA).
- Evaluation of patient response based on National Prostate Cancer Project (NPCP) criteria.
- Monitoring of serum prostate-specific antigen (PSA) levels and imaging for disease progression.
Main Results:
- Approximately 30% of evaluable patients achieved partial response.
- A 50% decrease in serum PSA levels was observed in some patients.
- Resolution of measurable lesions on imaging was noted.
- The therapy demonstrated a favorable safety profile with minimal adverse effects.
Conclusions:
- Dendritic cell vaccine therapy is a potential treatment option for hormone-refractory prostate cancer.
- PSMA-pulsed dendritic cells can induce anti-tumor immune responses.
- Combination therapy may enhance the synergistic effects of dendritic cell vaccines.